Amend the remaining claims as follows:

1. (Amended) A device for transdermal administration of topical therapeutic agents, comprising an applicator for applying an effective amount of a therapeutic agent to a tissue surface of a subject, and an ultrasound transducer, operatively coupled to the applicator, for providing ultrasound energy to the tissue surface at least one predetermined frequency to promote transdermal absorption of the drug through the tissue of the subject, wherein the ultrasound transducer further comprises at least one oscillating element capable of generating ultrasound energy at a frequency of between 100 kHz and 4 MHz .

3. (Amended) The device of either claim 1 or claim 51, wherein the ultrasound transducer further comprises at least one oscillating element capable of generating ultrasound energy at a power of about 0.02 to about 3 watts/cm^2.

4. (Amended) The device of either claim 1 or claim 51, wherein the device further comprises a controller for varying the frequency of the ultrasound energy.

5. (Amended) The device of either claim 1 or claim 51, wherein the device further comprises a controller for varying the power of the ultrasound energy.

6. (Amended) The device of either claim 1 or claim 51, wherein the device further comprises a compliant skin contacting material.

19. (Amended) The device of either claim 1 or claim 51, wherein the device further comprises a detector for monitoring feedback signals from the transducer.

Please add the following new claims:

51. (New) A device for transdermal administration of topical therapeutic agents, comprising an applicator for applying an effective amount of a therapeutic agent to a tissue surface of a subject; and an ultrasound transducer, operatively coupled to the applicator, for providing ultrasound energy to the tissue surface at least one predetermined frequency to promote transdermal absorption of the drug through the tissue of the subject and further comprising a pressure-sensitive switch.

52. (New) A device for transdermal administration of topical therapeutic agents, comprising an applicator for applying an effective amount of a therapeutic agent to a tissue surface of a subject; and an ultrasound transducer, operatively coupled to the applicator, for providing ultrasound energy to the tissue surface at least one predetermined frequency to promote transdermal absorption of the drug through the tissue of the subject, wherein the therapeutic agents are selected from the group consisting of papaverine, prostaglandin E1 (PGE 1), minoxidil, prostaglandins, organic nitrites, inhibitors of the renin-angiotensin system, inducible Nitric Oxide Synthase (iNOS) agents, and phosphodiesterase type 5 inhibitors.

53. (New) The device of claim 51 wherein the phosphodiesterase type 5 inhibitor is selected from the group consisting of sildenafil and alprostadil.

54. (New) A device for transdermal administration of topical therapeutic agents, comprising an applicator for applying an effective amount of a therapeutic agent to a tissue surface of a subject; and an ultrasound transducer, operatively coupled to the applicator, for providing ultrasound energy to the tissue surface at least one predetermined frequency to promote transdermal absorption of the drug through the tissue of the subject, wherein the therapeutic agents are selected from the group consisting of minoxidil, finasteride, fabao-101, cyproterone acetate, ethinyl estradiol, aldactone, and spironolactone.